Please login to the form below

Not currently logged in
Email:
Password:

SkyePharma shares fall as FDA queries asthma drug

SkyePharma's shares fell approximately 10 per cent as it warns of potential delays to the US launch of its flagship asthma treatment, Flutiform.

SkyePharma's shares fell approximately 10 per cent as it warned of potential delays to the US launch of its flagship asthma treatment, Flutiform.

The FDA, said the UK-based drug delivery firm, had questioned one particular aspect of the design of the phase III clinical trial programme.

SkyePharma revealed that the FDA query may force the company to conduct more clinical data to supplement the ongoing programme to satisfy the FDA and possibly delay the NDA until H2 2008.

Analysts had expected Skye Pharma to file for approval by Q4 2007 or Q1 2008, with a launch in Q2/ 3 2009.

Last week, GlaxoSmithKline's migraine drug, Trexima, was also held up by the FDA, after receiving only an approvable letter that asked the UK drug company for more safety data be before final approval was given.

CEO of SkyePharma, Frank Condella, refused to comment on what part of the clinical trial design the FDA had identified, but stressed that it was not a safety issue. He added that the programme had been positively reviewed by the FDA late 2005.

Shares in SkyePharma dropped 9.3 per cent to GBP 19.50 in am trading on 6 August.

6th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....